Background: Classical randomisation of clinical trial patients creates a source of genetic variance that may be contributing to the high failure rate seen in neurodegenerative disease trials. Our objective was to quantify genetic difference between randomised trial arms and determine how imbalance can affect trial outcomes.
Methods: 5851 patients with Parkinson's disease of European ancestry data and two simulated virtual cohorts based on public data were used. Data were resampled at different sizes for 1000 iterations and randomly assigned to the two arms of a simulated trial. False-negative and false-positive rates were estimated using simulated clinical trials, and per cent difference in genetic risk score (GRS) and allele frequency was calculated to quantify variance between arms.
Results: 5851 patients with Parkinson's disease (mean (SD) age, 61.02 (12.61) years; 2095 women (35.81%)) as well as simulated patients from virtually created cohorts were used in the study. Approximately 90% of the iterations had at least one statistically significant difference in individual risk SNPs between each trial arm. Approximately 5%-6% of iterations had a statistically significant difference between trial arms in mean GRS. For significant iterations, the average per cent difference for mean GRS between trial arms was 130.87%, 95% CI 120.89 to 140.85 (n=200). Glucocerebrocidase (GBA) gene-only simulations see an average 18.86%, 95% CI 18.01 to 19.71 difference in GRS scores between trial arms (n=50). When adding a drug effect of -0.5 points in MDS-UPDRS per year at n=50, 33.9% of trials resulted in false negatives.
Conclusions: Our data support the hypothesis that within genetically unmatched clinical trials, genetic heterogeneity could confound true therapeutic effects as expected. Clinical trials should undergo pretrial genetic adjustment or, at the minimum, post-trial adjustment and analysis for failed trials.
Keywords: clinical genetics; genetics; parkinson-s disease.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: ZG-O reports personal fees from Sanofi/Genzyme, Lysosomal Therapeutics, Idorsia, Denali, Prevail Therapeutics, Ventus, Deerfield and Allergan. ZG-O is also supported by the Fonds de recherche du Québec-Santé (FRQS) Chercheurs-boursiers award given in collaboration with Parkinson Quebec, and is a Parkinson Canada New Investigator awardee. AGD-W reports personal fees from Merck and Co and other from Biogen. DJS reports funding from Merck and Co.
Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug. Report No.: 17-05231-EF-1. Agency for Healthcare Research and Quality (US). 2018. PMID: 30256575 Free Books & Documents. Review.
Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Agency for Healthcare Research and Quality (US). 2018. PMID: 30354042 Free Books & Documents. Review.
Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1. Agency for Healthcare Research and Quality (US). 2018. PMID: 30085502 Free Books & Documents. Review.
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25. Lancet Neurol. 2017. PMID: 28958801 Free PMC article.
Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).Health Technol Assess. 2016 Aug;20(63):1-96. doi: 10.3310/hta20630. Health Technol Assess. 2016. PMID: 27580669 Free PMC article. Clinical Trial.
Cited by 2 articles
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.Neurobiol Dis. 2020 Apr;137:104782. doi: 10.1016/j.nbd.2020.104782. Epub 2020 Jan 25. Neurobiol Dis. 2020. PMID: 31991247 Review.
Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.Brain. 2020 Jan 1;143(1):234-248. doi: 10.1093/brain/awz350. Brain. 2020. PMID: 31755958 Free PMC article.